THE neoplasm commonly associated with hypoglycamia is the islet-cell tumour, or insulinoma. Unless malignant, the insulinoma is small. However, severe persistent disabling organic hypoglycaemia may be caused by a group of neoplasms which are not related to the pancreatic islets. These non-islet-cell tumours are nearly always huge, often weighing more than a kilogramme.
A convenient classification of tumours causing hypoglycamia (Table i) (Fig. i) .
In patients with insulinomas the fasting insulin is typically higher than the normal range for normoglycxemia controls, which is ig,uU per ml. S.D.47.5. A high level may, however, be missed, found in control subjects or in patients with mesenchymal tumours. In the latter, fasting insulin is not raised (Fig. 3) . The solitary exception, a 'black sheep', represents the only serum taken from one patient (Oleesky and others, I96I) . This case is exasperating, unless one postulates that the occasional non-islet cell tumour does stimulate the pancreatic islets. Multiple plasma samples failed to show a high insulin in all the other fibrosarcomas, but always revealed at least one abnormal level in all 20 insulinomas. We have found that the most useful single differential diagnostic test is plasma insulin assay at io-minute intervals for 20 to 30 minutes after the injection of ig. of Na tolbutamide i.v. There is a striking contrast between the exaggerated plasma insulin response in insulinomas (Fig. 4) and cofntrol subjects. In mesenchymal tumours the equivalent plasma insulin response is either normal or depressed.
In the insulinomas there is also an excessive rise in insulin after ingestion of L-leucine (Samols and Marks, I963) . A similar response is seen in children with 'leucine-sensitivity', probably because their islet cells are hyperactive and hyperplastic. L-leucine induces only a small rise in plasma insulin in normal subjects. Yet the normal regulatory mechanism for insulin secretion, the (Fig. 6) . Similarly, a prolonged glucose tolerance curve will always show hypoglycemia after four to five hours in this group. Insulinomas and mesenchymal tumours may produce any shape of glucose tolerance curve, but the late, prolonged hyperglyczmia or 'diabetic' pattern (Fig. 6 ) is usual in mesenchymal tumours and not uncommon in insulinomas. Demonstration of Whipple's triad is a sophisticated way of saying that a patient has persistent fasting hypoglycoamia.
Mechanism of Hypoglycaemia in Mesenchymal Tumours
It is reasonable to assume that the tumour is in some way responsible for hypoglycaemia because removal of the tumour results in normoglycemia.
The mechanism is tantalizingly baffling because it looks simple. Basically, hypoglycaemia is caused by either:
(i) Increased rate of disappearance of glucose from the blood; (ii) decreased hepatic output of glucose; or (iii) both (i) and (ii) occurring simultaneously. Insulin may act by (i), (ii) or (iii). A hypothetical insulin-like substance, often called 'in- sulinoid', could presumably do the same. The third possibility, suggested by the large size of these neoplasms, is a 'hungry' tumour, consuming glucose excessively.
The rate of disappearance of glucose from the blood stream is considered an index of tissue glucose assimilation when measured by intravenous glucose tolerance tests. Tracer amounts of radioactive (14C) glucose will not affect the blood glucose level, which rises after a 25-g. load of unlabelled (12C) glucose. The higher the glucose assimilation coefficient (K) the faster is the rate of disappearance. Fig. 7 shows that hypoglycxmia is primarily caused by excessive glucose utilization, as the pre-operative K values during constant hypoglycaemia and after a load of glucose are higher than the post-operative K figures for both '4C and 12C glucose. This should not occur if a -decreased hepatic glucose output was solely responsible for the hypoglycmemia.
F.F.A. levels are remarkably low pre-operatively during hypoglycaemia. In another case a very low F.F.A. level persisted for some time during hypoglycamia, but did eventually rise (Fig. 6) . The interest of this finding is that insulin is the only human hormone known to cause the combination of hypoglycxmia + low F.F.A.
Finally, it can be shown that there is also some suppression of hepatic glucose output because of the 'hypoglycsemia unresponsiveness' after intravenous glucose pre-operatively (Fig. 7) . The effect of injecting glucagon confirms such suppression, as the extra stimulus is able to release hepatic glucose during hypoglycxmia. Hepatic glycogen stores were adequate, as hyperglycemia could be induced by the glucagon (Fig. 8) .
The tenta-:ive conclusions drawn are: (a) The tu mour may produce a substance which increases sensitivity to insulin. This could account for all the findings, including the immediate post-operative behaviour of glucose and F.F.A. (Fig. 7) . This transient 'diabetic' state could be due to the unopposed action of hormonal or other insulin antagonists which take a while to disappear. (b) Insulinoid is still a possibility. (c) If the tumour is 'hungry' for glucose, it must, in addition, be producing substances suppressing both lipolysis (to cause the low F.F.A. level) and hepatic glucose output.
The alternatives ((a), (b)) are perhaps more acceptable in theory, since the metabolic gymnastics require only one hypothetical event. The role of insulin may soon be tested directly, by injection of anti-insulin antiserum. The antiserum would neutralize circulating insulin temporarily. Although hypoglycxmic substances (insulinoid) have been demonstrated in these tumours, such insulinoid appears to be present in neoplasms not associated with hypoglycamia and in normal tissues. It is tempting to imagine that large non-islet-cell epithelial tumours share a similar hypoglycamic mechanism with the mesenchymal tumours.
In conclusion, tumours causing hypoglycemia may be diagnosed with greater certainty today with the help of insulin assay. Insulinomas cause hypoglycxmia by hypersecretion of insulin, but non-islet-cell tumours probably cause hypoglycaemia by increasing sensitivity to endogenous insulin or by producing an insulin-like substance.
